Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multicentric Randomized Phase III Study Comparing High Doses of Chemotherapy With Rituximab Followed by Auto-transplant HPC Versus CHOP Plus Rituximab as First Line Therapy in High Risk Patients With DLBCL Non-Hodgkin's Lymphomas

NCT00355199 is registered in ClinicalTrials.gov with Gruppo Italiano Terapie Innovative nei Linfomi as lead sponsor.

NCT NCT00355199
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00355199 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multicentric Randomized Phase III Study Comparing High Doses of Chemotherapy With Rituximab Followed by Auto-transplant HPC Versus CHOP Plus Rituximab as First Line Therapy in High Risk Patients With DLBCL Non-Hodgkin's Lymphomas
Lead sponsor
Gruppo Italiano Terapie Innovative nei Linfomi
Phase
Phase 3
Overall status
Completed
Start date
May 31, 2005
Completion date
March 31, 2013
Enrollment
246 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

diffuse large b-cell lymphoma